Product Name :
Ladarixin sodium
Description:
Ladarixin sodium (DF 2156A) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin sodium can be used for the research of COPD and asthma.
CAS:
865625-56-5
Molecular Weight:
397.32
Formula:
C11H11F3NNaO6S2
Chemical Name:
sodium methanesulfonyl[(2R)-2-[4-(trifluoromethanesulfonyloxy)phenyl]propanoyl]azanide
Smiles :
[Na+].CS(=O)(=O)[N-]C(=O)[C@H](C)C1C=CC(=CC=1)OS(=O)(=O)C(F)(F)F
InChiKey:
QICAUCDBOAKDNS-OGFXRTJISA-M
InChi :
InChI=1S/C11H12F3NO6S2.Na/c1-7(10(16)15-22(2,17)18)8-3-5-9(6-4-8)21-23(19,20)11(12,13)14;/h3-7H,1-2H3,(H,15,16);/q;+1/p-1/t7-;/m1./s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Ladarixin sodium (DF 2156A) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin sodium can be used for the research of COPD and asthma.|Product information|CAS Number: 865625-56-5|Molecular Weight: 397.32|Formula: C11H11F3NNaO6S2|Chemical Name: sodium methanesulfonyl[(2R)-2-[4-(trifluoromethanesulfonyloxy)phenyl]propanoyl]azanide|Smiles: [Na+].CS(=O)(=O)[N-]C(=O)[C@H](C)C1C=CC(=CC=1)OS(=O)(=O)C(F)(F)F|InChiKey: QICAUCDBOAKDNS-OGFXRTJISA-M|InChi: InChI=1S/C11H12F3NO6S2.Na/c1-7(10(16)15-22(2,17)18)8-3-5-9(6-4-8)21-23(19,20)11(12,13)14;/h3-7H,1-2H3,(H,15,16);/q;+1/p-1/t7-;/m1./s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Tarextumab} site|{Tarextumab} Stem Cell/Wnt|{Tarextumab} Purity & Documentation|{Tarextumab} Purity|{Tarextumab} manufacturer|{Tarextumab} Autophagy} |Shelf Life: ≥12 months if stored properly.{{Betamethasone dipropionate} medchemexpress|{Betamethasone dipropionate} Glucocorticoid Receptor|{Betamethasone dipropionate} Protocol|{Betamethasone dipropionate} Data Sheet|{Betamethasone dipropionate} supplier|{Betamethasone dipropionate} Epigenetic Reader Domain} |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.PMID:23415682 |Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Ladarixin inhibits human polymorphonuclear leukocyte (PMN) migration to CXCL8 (IC50 at 0.7 nM).|In Vivo:|Ladarixin (10 mg/kg; p.o. once a day) reduces allergic airway inflammation in a model of single OVA exposure. Ladarixin reduces allergic airway inflammation, remodeling, and bronchial hyperreactivity in a model of chronic OVA exposure. Ladarixin (10 mg/kg; p.o. once a day for 8 days) reduces pulmonary inflammation and fibrosis induced by bleomycin in mice. Ladarixin (10 mg/kg; p.o. once a day for 3 days) protects mice from cigarette smoke-induced exacerbation of influenza-A infection. Ladarixin is also effective in decreasing CXCL8-induced polymorphonuclear leukocyte infiltration in several animal models without a significant dose-related reduction in systemic neutrophil counts.|Products are for research use only. Not for human use.|
